Microglia in Alzheimer Disease: Well-Known Targets and New Opportunities

被引:222
|
作者
Hemonnot, Anne-Laure [1 ]
Hua, Jennifer [1 ]
Ulmann, Lauriane [1 ]
Hirbec, Helene [1 ]
机构
[1] Univ Montpellier, CNRS, Inst Funct Genom IGF, INSERM, Montpellier, France
来源
FRONTIERS IN AGING NEUROSCIENCE | 2019年 / 11卷
关键词
Alzheimer disease; microglia; neuroinflammation; microglia diversity; purinergic signaling; sexual dimorphism; early stage; hiPSCs; AMYLOID-BETA-PEPTIDE; PLURIPOTENT STEM-CELLS; MILD COGNITIVE IMPAIRMENT; HUMAN APOLIPOPROTEIN-E; MOUSE MODEL; SEX-DIFFERENCES; A-BETA; MICROCEBUS-MURINUS; APOE GENOTYPE; SIGNAL-TRANSDUCTION;
D O I
10.3389/fnagi.2019.00233
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Microglia are the resident macrophages of the central nervous system. They play key roles in brain development, and physiology during life and aging. Equipped with a variety of molecular sensors and through the various functions they can fulfill, they are critically involved in maintaining the brain's homeostasis. In Alzheimer disease (AD), microglia reaction was initially thought to be incidental and triggered by amyloid deposits and dystrophic neurites. However, recent genome-wide association studies have established that the majority of AD risk loci are found in or near genes that are highly and sometimes uniquely expressed in microglia. This leads to the concept of microglia being critically involved in the early steps of the disease and identified them as important potential therapeutic targets. Whether microglia reaction is beneficial, detrimental or both to AD progression is still unclear and the subject of intense debate. In this review, we are presenting a state-of-knowledge report intended to highlight the variety of microglial functions and pathways shown to be critically involved in AD progression. We first address both the acquisition of new functions and the alteration of their homeostatic roles by reactive microglia. Second, we propose a summary of new important parameters currently emerging in the field that need to be considered to identify relevant microglial targets. Finally, we discuss the many obstacles in designing efficient therapeutic strategies for AD and present innovative technologies that may foster our understanding of microglia roles in the pathology. Ultimately, this work aims to fly over various microglial functions to make a general and reliable report of the current knowledge regarding microglia's involvement in AD and of the new research opportunities in the field.
引用
收藏
页数:20
相关论文
共 50 条
  • [31] SOME NEW PHOTOGRAPHS OF WELL-KNOWN MITHRAIC MONUMENTS
    GORDON, RL
    HINNELLS, JR
    JOURNAL OF MITHRAIC STUDIES, 1978, 2 (02): : 198 - 223
  • [32] Well-known medicinal plants with new therapeutic activity?
    Grohs, Birgit
    ZEITSCHRIFT FUR ARZNEI- & GEWURZPFLANZEN, 2014, 19 (02): : 57 - 57
  • [33] Kaixinsan, a Well-Known Chinese Herbal Prescription, for Alzheimer's Disease and Depression: A Preclinical Systematic Review
    Fu, Huan
    Xu, Zhen
    Zhang, Xi-le
    Zheng, Guo-qing
    FRONTIERS IN NEUROSCIENCE, 2020, 13
  • [34] WELL-KNOWN TRADEMARKS IN BRAZIL
    ARRUDA, MJG
    IIC-INTERNATIONAL REVIEW OF INDUSTRIAL PROPERTY AND COPYRIGHT LAW, 1981, 12 (04): : 524 - 525
  • [35] ON A WELL-KNOWN IMPROPER INTEGRAL
    HARUKI, H
    AMERICAN MATHEMATICAL MONTHLY, 1967, 74 (07): : 846 - &
  • [36] The Myth of the Well-Known Client
    Lakeman, Richard
    ISSUES IN MENTAL HEALTH NURSING, 2019, 40 (02) : 191 - 193
  • [37] A WELL-KNOWN PHALLACY RESURRECTED
    HOBBS, JT
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 1989, 41 (03): : 299 - 299
  • [38] A WELL-KNOWN EIGENVALUE PROBLEM
    HERSH, R
    AMERICAN MATHEMATICAL MONTHLY, 1965, 72 (02): : 190 - &
  • [39] WELL-KNOWN MARKS PROTECTION TO HIGH AND KNOWN
    Pereira, Daniel Queiroz
    Jacob, Paola Domingues
    QUAESTIO IURIS, 2013, 6 (01): : 1 - 29
  • [40] PHARMACOKINETICS AND BIOTRANSFORMATION OF WELL-KNOWN
    SPECK, U
    NAGEL, R
    LEISTENSCHNEIDER, W
    MUTZEL, W
    FORTSCHRITTE AUF DEM GEBIETE DER RONTGENSTRAHLEN UND DER NUKLEARMEDIZIN, 1977, 127 (03): : 270 - 274